BR112015022096A2 - moduladores de canal de sódio para o tratamento da dor - Google Patents
moduladores de canal de sódio para o tratamento da dorInfo
- Publication number
- BR112015022096A2 BR112015022096A2 BR112015022096A BR112015022096A BR112015022096A2 BR 112015022096 A2 BR112015022096 A2 BR 112015022096A2 BR 112015022096 A BR112015022096 A BR 112015022096A BR 112015022096 A BR112015022096 A BR 112015022096A BR 112015022096 A2 BR112015022096 A2 BR 112015022096A2
- Authority
- BR
- Brazil
- Prior art keywords
- sodium channel
- channel modulators
- pain treatment
- compounds
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
resumo moduladores de canal de sódio para o tratamento da dor a presente invenção se refere a compostos moduladores de canal de sódio, em particular compostos moduladores de nav1.7 de fórmula i: fórmula (i). em particular, proporcionados aqui são processos para a preparação de intermediários usados na preparação de composições farmacêuticas que compreendem, e métodos terapêuticos que compreendem administrar os referidos compostos. em particular, proporcionados aqui são compostos para o tratamento da dor. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361787618P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/025809 WO2014151472A1 (en) | 2013-03-15 | 2014-03-13 | Sodium channel modulators for the treatment of pain |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015022096A2 true BR112015022096A2 (pt) | 2017-07-18 |
BR112015022096A8 BR112015022096A8 (pt) | 2019-11-26 |
Family
ID=51580969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015022096A BR112015022096A8 (pt) | 2013-03-15 | 2014-03-13 | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos |
Country Status (16)
Country | Link |
---|---|
US (1) | US10179781B2 (pt) |
EP (1) | EP2968234B1 (pt) |
JP (1) | JP6449845B2 (pt) |
KR (1) | KR20150131254A (pt) |
CN (1) | CN105188694B (pt) |
AU (1) | AU2014234105B2 (pt) |
BR (1) | BR112015022096A8 (pt) |
CA (1) | CA2900604A1 (pt) |
ES (1) | ES2687481T3 (pt) |
HK (1) | HK1219060A1 (pt) |
IL (1) | IL242564A0 (pt) |
MX (1) | MX363680B (pt) |
MY (1) | MY188139A (pt) |
PH (1) | PH12015501740A1 (pt) |
RU (1) | RU2669367C2 (pt) |
WO (1) | WO2014151472A1 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013064984A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
EA026393B1 (ru) | 2012-05-22 | 2017-04-28 | Дженентек, Инк. | N-замещенные бензамиды и их применение в лечении боли |
KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF |
ES2687481T3 (es) | 2013-03-15 | 2018-10-25 | Chromocell Corporation | Moduladores del canal de sodio para el tratamiento del dolor |
WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
BR112016005271A2 (pt) * | 2013-09-10 | 2020-05-12 | Chromocell Corporation | Moduladores de canais de sódio para o tratamento da dor e do diabetes |
EP3450428A1 (en) | 2013-11-27 | 2019-03-06 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
EP3193610A4 (en) * | 2014-09-09 | 2018-04-04 | Chromocell Corporation | Selective nav1.7 inhibitors for the treatment of diabetes |
CN104710379B (zh) * | 2015-03-09 | 2017-01-18 | 华南理工大学 | 一种bms‑191011的合成方法 |
KR20180008761A (ko) | 2015-05-22 | 2018-01-24 | 제넨테크, 인크. | 치환된 벤즈아미드 및 이의 이용 방법 |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
JP6934196B2 (ja) | 2015-10-07 | 2021-09-15 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティ オブ アリゾナ | Crmp2のsumo付加抑制剤 |
EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
PE20181495A1 (es) | 2015-12-18 | 2018-09-18 | Merck Sharp & Dohme | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje |
JP2019513714A (ja) | 2016-03-30 | 2019-05-30 | ジェネンテック, インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
CA3039853A1 (en) | 2016-10-17 | 2018-04-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック, インコーポレイテッド | ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体 |
TW202000651A (zh) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | 治療性組成物及其使用方法 |
CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
WO2019200369A1 (en) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage |
WO2019217822A1 (en) * | 2018-05-11 | 2019-11-14 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions |
CA3108792A1 (en) | 2018-09-10 | 2020-03-19 | Kaken Pharmaceutical Co., Ltd. | Novel heteroaromatic amide derivative and medicament containing the same |
EP3920930A4 (en) * | 2019-02-04 | 2023-03-08 | Simon Fraser University | METHODS AND COMPOUNDS FOR INHIBITION OF INACTIVATION OF VOLTAGE-SENSITIVE SODIUM CHANNELS |
CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905971A (en) * | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
BR0208244A (pt) * | 2001-03-14 | 2004-03-02 | Gr Nenthal Gmbh | Pirazolo-e tiazolopirinidinas substituìdas |
US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
RU2006107211A (ru) * | 2003-08-08 | 2007-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Композиции, полезные в качестве ингибиторов потенциалозависимых натриевых каналов |
GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
US7449477B2 (en) | 2003-11-25 | 2008-11-11 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) |
MXPA06012613A (es) | 2004-05-07 | 2007-01-31 | Amgen Inc | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. |
CA2574600C (en) * | 2004-07-23 | 2010-08-31 | Pfizer Inc. | Pyridine derivatives |
BRPI0517263A (pt) | 2004-10-29 | 2008-10-07 | Astrazeneca Ab | novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias |
AR054394A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
WO2007078990A2 (en) | 2005-12-23 | 2007-07-12 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
CA2694748A1 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
EP2173743A2 (en) * | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
GEP20135992B (en) | 2009-01-12 | 2013-12-25 | Icagen Inc | Sulfonamide derivatives |
EP3632899A1 (en) | 2009-05-29 | 2020-04-08 | RaQualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
JP2013525368A (ja) | 2010-04-23 | 2013-06-20 | キネタ・インコーポレイテツド | 抗ウイルス性化合物 |
JP5860045B2 (ja) * | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドPfizer Limited | 化合物 |
ES2533065T3 (es) | 2010-07-09 | 2015-04-07 | Pfizer Limited | Bencenosulfonamidas útiles como inhibidores de los canales de sodio |
ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
CA2804877A1 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
KR20140009311A (ko) | 2011-01-18 | 2014-01-22 | 암젠 인크 | Nav1.7 넉아웃 마우스 및 이의 용도 |
MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
WO2013043925A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
WO2013064984A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
US9757379B2 (en) | 2012-11-14 | 2017-09-12 | The Board Of Regents Of The University Of Texas System | Inhibition of HIF-2α heterodimerization with HIF1β (ARNT) |
ES2687481T3 (es) | 2013-03-15 | 2018-10-25 | Chromocell Corporation | Moduladores del canal de sodio para el tratamiento del dolor |
ES2739433T3 (es) | 2013-09-09 | 2020-01-31 | Peloton Therapeutics Inc | Aril éteres y usos de los mismos |
BR112016005271A2 (pt) | 2013-09-10 | 2020-05-12 | Chromocell Corporation | Moduladores de canais de sódio para o tratamento da dor e do diabetes |
-
2014
- 2014-03-13 ES ES14767550.8T patent/ES2687481T3/es active Active
- 2014-03-13 CA CA2900604A patent/CA2900604A1/en active Pending
- 2014-03-13 US US14/776,016 patent/US10179781B2/en active Active
- 2014-03-13 AU AU2014234105A patent/AU2014234105B2/en not_active Ceased
- 2014-03-13 JP JP2016501972A patent/JP6449845B2/ja active Active
- 2014-03-13 EP EP14767550.8A patent/EP2968234B1/en not_active Not-in-force
- 2014-03-13 RU RU2015133310A patent/RU2669367C2/ru not_active IP Right Cessation
- 2014-03-13 KR KR1020157029193A patent/KR20150131254A/ko active IP Right Grant
- 2014-03-13 CN CN201480014410.XA patent/CN105188694B/zh not_active Expired - Fee Related
- 2014-03-13 BR BR112015022096A patent/BR112015022096A8/pt not_active IP Right Cessation
- 2014-03-13 WO PCT/US2014/025809 patent/WO2014151472A1/en active Application Filing
- 2014-03-13 MX MX2015011907A patent/MX363680B/es unknown
- 2014-03-13 MY MYPI2015702635A patent/MY188139A/en unknown
-
2015
- 2015-08-07 PH PH12015501740A patent/PH12015501740A1/en unknown
- 2015-11-12 IL IL242564A patent/IL242564A0/en unknown
-
2016
- 2016-06-22 HK HK16107214.7A patent/HK1219060A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HK1219060A1 (zh) | 2017-03-24 |
WO2014151472A1 (en) | 2014-09-25 |
US20160046617A1 (en) | 2016-02-18 |
RU2015133310A (ru) | 2017-04-20 |
MX2015011907A (es) | 2016-05-16 |
CA2900604A1 (en) | 2014-09-25 |
JP6449845B2 (ja) | 2019-01-09 |
RU2015133310A3 (pt) | 2018-02-28 |
EP2968234B1 (en) | 2018-06-27 |
US10179781B2 (en) | 2019-01-15 |
JP2016512844A (ja) | 2016-05-09 |
CN105188694B (zh) | 2018-07-31 |
BR112015022096A8 (pt) | 2019-11-26 |
ES2687481T3 (es) | 2018-10-25 |
PH12015501740A1 (en) | 2015-10-19 |
IL242564A0 (en) | 2016-02-29 |
MX363680B (es) | 2019-03-29 |
EP2968234A4 (en) | 2016-10-12 |
MY188139A (en) | 2021-11-23 |
CN105188694A (zh) | 2015-12-23 |
RU2669367C2 (ru) | 2018-10-11 |
KR20150131254A (ko) | 2015-11-24 |
AU2014234105B2 (en) | 2019-01-03 |
AU2014234105A1 (en) | 2015-09-03 |
EP2968234A1 (en) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015022096A2 (pt) | moduladores de canal de sódio para o tratamento da dor | |
BR112016005271A2 (pt) | Moduladores de canais de sódio para o tratamento da dor e do diabetes | |
CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
EA201490864A1 (ru) | Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов | |
MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
GEP20207102B (en) | Sulfonamides as modulators of sodium channels | |
BR112015017997A8 (pt) | amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso | |
UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
BR112015014349A2 (pt) | derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente | |
EA201490888A1 (ru) | Новые производные пурина и их применение для лечения заболевания | |
BR112015000578A2 (pt) | moduladores da via do complemento e usos dos mesmos | |
BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
BR112015010779A2 (pt) | moduladores de di-hidropirazol gpr40 | |
PH12017500533A1 (en) | 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
MA39778A (fr) | Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants | |
BR112015004523A2 (pt) | compostos de tetraciclina | |
PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
BR112015015250A2 (pt) | derivados de pirrolidina, composições farmacêuticas e usos dos mesmos | |
BR112015006243A2 (pt) | agentes antibacterianos de fenicol | |
BR112017015597A2 (pt) | moduladores dos receptores da adenosina a3 | |
UA115307C2 (uk) | Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2623 DE 13/04/2021. |